PMID- 38068417
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231209
IS  - 2077-0383 (Print)
IS  - 2077-0383 (Electronic)
IS  - 2077-0383 (Linking)
VI  - 12
IP  - 23
DP  - 2023 Nov 28
TI  - Assessing the Effects of 0.3% Carboxymethylcellulose Tear Substitute Treatment on 
      Symptoms and Signs of Dry Eye Disease in Elderly Population: A Prospective 
      Longitudinal Study.
LID - 10.3390/jcm12237364 [doi]
LID - 7364
AB  - BACKGROUND: We aimed to evaluate the effects of 0.3% carboxymethylcellulose (CMC) 
      tear substitute treatment in dry eye disease (DED), as well as treatment 
      compliance and adverse events (AEs). METHODS: In this prospective, longitudinal 
      study, a total of 30 eyes receiving 0.3% CMC tear substitute four times daily for 
      DED were evaluated. Clinical endpoints included an ocular surface disease index 
      (OSDI) questionnaire, average non-invasive tear film break-up time (A-NIBUT), 
      lipid layer thickness (LLT), and a Schirmer test with anesthesia (ST). Treatment 
      compliance and AEs were also assessed. All evaluations were performed at 2, 4, 
      and 12 weeks of follow-up. RESULTS: At the end of the follow-up, significant 
      improvement was observed in all clinical endpoints with the following mean 
      values: DeltaOSDI questionnaire of -22.53 +/- 14.68 points, DeltaA-NIBUT of 4.81 +/- 2.88 s, 
      DeltaLLT of 5.63 +/- 6.53 nm, and DeltaST of 2.8 +/- 2.1 mm (p < 0.001 for all comparisons). 
      Although repeated measures analysis showed that all clinical endpoints presented 
      statistically significant differences (p < 0.001 for all comparisons 
      LLT(Baseline)-LLT(2-weeks) (p = 0.460) and LLT(4-weeks)-LLT(12-weeks) (p = 0.071) 
      were the only pairs of measures that reported non-statistically significant 
      differences). In addition, treatment compliance was 94.3 +/- 5.2% and transient AEs 
      related to the use of 0.3% CMC tear substitute were reported. CONCLUSIONS: 0.3% 
      CMC tear substitute treatment seems to achieve beneficial effects on the OSDI 
      questionnaire, A-NIBUT, LLT, and ST. However, further studies at this 
      concentration are needed to confirm these results.
FAU - Ballesteros-Sanchez, Antonio
AU  - Ballesteros-Sanchez A
AUID- ORCID: 0000-0002-9248-8685
AD  - Department of Physics of Condensed Matter, Optics Area, University of Seville, 
      41004 Seville, Spain.
AD  - Department of Ophthalmology, Clinica Novovision, 30008 Murcia, Spain.
FAU - Sanchez-Gonzalez, Jose-Maria
AU  - Sanchez-Gonzalez JM
AUID- ORCID: 0000-0003-0450-7717
AD  - Department of Physics of Condensed Matter, Optics Area, University of Seville, 
      41004 Seville, Spain.
FAU - Tedesco, Giovanni Roberto
AU  - Tedesco GR
AUID- ORCID: 0000-0003-1350-3398
AD  - Studio Oculistica Tedesco, 88024 Girifaldo, Italy.
FAU - Rocha-De-Lossada, Carlos
AU  - Rocha-De-Lossada C
AUID- ORCID: 0000-0001-7464-2493
AD  - Qvision, Ophthalmology Department, VITHAS Almeria Hospital, 04120 Almeria, Spain.
AD  - Ophthalmology Department, VITHAS Malaga, 29016 Malaga, Spain.
AD  - Regional University Hospital of Malaga, Hospital Civil Square, 29009 Malaga, 
      Spain.
AD  - Department of Surgery, Ophthalmology Area, University of Seville, 41009 Seville, 
      Spain.
FAU - Murano, Gianluca
AU  - Murano G
AD  - Sacro Cuore-iGreco Ospedali Riuniti, 87100 Cosenza, Italy.
FAU - Spinelli, Antonio
AU  - Spinelli A
AD  - Biomeeting, 89123 Reggio Calabria, Italy.
FAU - Borroni, Davide
AU  - Borroni D
AUID- ORCID: 0000-0001-6952-5647
AD  - Departament of Ophthalmology, Riga Stradins University, LV-1007 Riga, Latvia.
AD  - Centro Oculistico Borroni, 21013 Gallarate, Italy.
AD  - Eyemetagenomics Ltd., London WC2H 9JQ, UK.
LA  - eng
PT  - Journal Article
DEP - 20231128
PL  - Switzerland
TA  - J Clin Med
JT  - Journal of clinical medicine
JID - 101606588
PMC - PMC10707251
OTO - NOTNLM
OT  - artificial tears
OT  - carboxymethylcellulose (CMC)
OT  - dry eye disease (DED)
OT  - meibomian gland dysfunction (MGD)
OT  - tear substitutes
COIS- Author Davide Borroni was employed by the company Eyemetagenomics. The remaining 
      authors declare that the research was conducted in the absence of any commercial 
      or financial relationships that could be construed as a potential conflict of 
      interest.
EDAT- 2023/12/09 10:43
MHDA- 2023/12/09 10:44
PMCR- 2023/11/28
CRDT- 2023/12/09 01:10
PHST- 2023/10/11 00:00 [received]
PHST- 2023/11/13 00:00 [revised]
PHST- 2023/11/27 00:00 [accepted]
PHST- 2023/12/09 10:44 [medline]
PHST- 2023/12/09 10:43 [pubmed]
PHST- 2023/12/09 01:10 [entrez]
PHST- 2023/11/28 00:00 [pmc-release]
AID - jcm12237364 [pii]
AID - jcm-12-07364 [pii]
AID - 10.3390/jcm12237364 [doi]
PST - epublish
SO  - J Clin Med. 2023 Nov 28;12(23):7364. doi: 10.3390/jcm12237364.